The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Thanks. You’ve cheered me up after a sh*tty week.
Yes that’s absolutely true, it was the antibody that failed.
My post was absolutely not about Affimers failing in AffiDX, it was just some general thoughts following the bruising week we’ve just had, which WAS absolutely not the fault of the Affimer platform.
Poirot
unless i`m mistaken, if you read the last RNS, I thought it said they had pulled the test because it was the antibodies that wasn`t performing not the Affimers.
I will stand corrected if i`ve read it wrong ?
Naturally after a week like we’ve had doubts may start to creep in about wether the technology can truly compete with antibodies. Well, I’ve spent the last few days going back through my research and I still can’t find any reasons why the Affimer technology can’t compete in all the fields Antibodies operate in.
The facts are that Affimers have great binding affinity typically in the nanomolar range, similar to antibodies. There incredibly specific, easy to produce, are stable, have low cost of manufacture and have freedom to operate around antibody IP. However, the company does need to do a better job of commercialising the technology and I’d certainly like to see more deals like the Astrea and Biokit. I suspect we will also see the next AffiDX product launched in 2022 for Cortisol(stress). I’m happy that the company is now pushing ahead with its own products now as the licensing route is far too slow.
On the therapeutics side, Affimers have demonstrated the necessary properties for a therapeutic platform. The animal studies for the PD-L1 Affimer absolutely proved that they can inhibit tumour growth, they actually performed as well as marketed antibodies The only issue I could find during my research was half-life properties with rapid kidney clearance. However the Affimer XT progress has seemingly solved this issue, clearly LG think so and are now in pre-clinical development with a PD-L1/XT bi-specific Affimer.
Regardless of the past week I’m still hugely excited about what the Affimer platform and it’s potential to compete with antibodies in all fields. Of course we also have Precision which potentially addresses an even bigger market and nothing has made me worry on that front yet. All we’ve had since 1st dosing, is Al telling us he’s pleased with progress, extra hospitals opening up and IND approval, the submission would have had to include early data from the 1st patient. I do however believe that AVA600 is running several weeks late due to covid, but we could get news on that any day now.
Anyway a bruising week, but if there is one share that can easily recover from these setbacks it’s Avacta.
GLA.
Positive start to the day,all trolls filtered ,Love it.
Thanks for sharing. It’s adds even more value to the LG Chem partnership renewal.
I forgot to include the link for the $4.8 billion purchase of the Ablynx nanobody platform by Sanofi in 2018:
June 20, 2018
Sanofi Completes $4.8-Billion Ablynx Acquisition
https://www.pharmtech.com/view/sanofi-completes-48-billion-ablynx-acquisition
Imagine the Avacta Mkt Cap if they only ever reach just 10% of the £100 BILLION+ antibody market. That's just the Affimer platform. Doesn't even include the substantially larger Precision platform for Cancer et Al.
Affimers (and nanobodies) will eventually completely replace the £100 billion+ antibody market.
There is no point in including Aptamers (mentioned in the clinical study below) as "Affimer technology has been engineered to overcome many of the problems associated with aptamers or with antibodies and possess a number of unique key benefits."
Avacta website has a page showing how superior their Affimer technology is compared to the Aptamer technology here:
An Affimer is not an aptamer
https://avacta.com/2014-06-20/
Also,regarding the other competing technology referred to in the study below, Nanobody technology. I would like to remind investors that the inventors of the Nanobody technology, ABLYNX, were bought by Sanofi in 2018 for $4.8 billion:
https://www.pharmtech.com/view/sanofi-completes-48-billion-ablynx-acquisition
The Nanobody platform is very similar to the Avacta Affimer platform as they are both direct competitors in the £100 billion+ antibody market and are both small alternatives to antibodies.
However, Avacta have just started extremely exciting Cancer trials via their Precision platform and also have the potentially very lucrative Affidx covid treatment for years to come to fund all future Cancer trials.
If Sanofi were prepared to pay $4.8 billion for the Ablynx Nanobody platform in 2018 then how much will the Avacta Affimer and Precision platforms be sold for in the future ?
Clearly Avacta are heading to the FTSE100 in the coming years.
However, I think it is almost certain that they will be bought well before for a sum in excess of the $4.8 billion paid for Ablynx,especially if Avacta list in the USA as AS has previously said is part of the plan.
Great find thanks, incredibly we are sat here with a MC under £200 million.
That new clinical study says:
Consequently, there is a trend towards using smaller nanobodies, affimers, and aptamers instead of the conventional primary–secondary antibody complexes"
If you read the Avacta website you will see what AS has repeatedly said.
Avacta are targeting the $100 billion+ market due to Affimers being "size (10x smaller than antibodies), stability, versatility, rapid development and ease of production."
AVACTA WEBSITE:
https://avacta.com/investors/key-information/
"Affimers are engineered alternatives to antibodies that have significant competitive advantages including size, stability, versatility, rapid development and ease of production. Despite their shortcomings, antibodies currently dominate markets, such as diagnostics and therapeutics, worth in excess of $100 billion."
AFFIMER essential advantages over other technologies:
https://avacta.com/therapeutics/affimer-technology/
14 Jan 2022
Minimal genetically encoded tags for fluorescent protein labeling in living neurons
https://www.nature.com/articles/s41467-022-27956-y
"Breaking the resolution limit in modern super-resolution microscopy techniques has brought about a demand for small labeling tags that bring the fluorophore closer to the target.
Consequently, there is a trend towards using smaller nanobodies, affimers, and aptamers instead of the conventional primary–secondary antibody complexes"
--------------------------------------------------------